Delivering Cutting-Edge Technology

TSO3 is Positioned for Success Today and in the Future.

TSO3 is a commercialization-stage medical device company providing cutting-edge low temperature terminal sterilization technology that offers an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals and ambulatory surgical facilities. TSO3’s flagship product is the STERIZONE® VP4 Sterilizer – a low-temperature sterilization system that utilizes the dual sterilants of vaporized hydrogen peroxide (H2O2) and ozone (O3) to achieve terminal sterilization of heat and moisture sensitive medical devices. The STERIZONE VP4 Sterilizer is the only Food and Drug Administration (FDA) cleared low temperature sterilizer that can process large 75 lb mixed instrument loads and is also the only terminal sterilization method that is FDA cleared and validated to sterilize long, complex multi-channel flexible endoscopes that fall within certain dimensions, such as colonoscopes, gastroscopes and duodenoscopes (see claims at

TSO3’s global market opportunity includes the traditional low temperature sterilization applications in the $6 billion sterilization industry in over 25,000 hospitals, as well as a burgeoning unique opportunity to terminally sterilize over 50 million annual colonoscopies, gastroscopies and other endoscopic procedures.

Our business model includes the sale of the sterilizer, as well as recurring revenue from the sale of consumables and services. With a rapidly evolving healthcare industry that is mandating the sterilization of more devices, and outstanding customer reviews from our existing and growing user base, TSO3 is poised to significantly disrupt the existing large and well defined global market with innovative sterilization technologies that provide safe care for patients, and save money and increase efficiency for healthcare facilities.

Latest News and Events

Stay up to date on important investor news and information.

Meet our team.

Get to know the management team and board of directors.

Analyst Coverage

Frédéric Tremblay Desjardins Capital Markets 514.841.0283
Douglas W. Loe Echelon Wealth Partners Inc. 416.775.1004
Nick Agostino Laurentian Bank Securities, Inc. 416.865.5967
Douglas Miehm RBC Capital Markets 416.842.7823

Any opinions, estimates or forecasts regarding TSO3‘s performance made by analysts are theirs alone and do not represent the opinions, forecasts or predictions of TSO3 Inc. or its management. TSO3 does not, by its reference on this website, imply its endorsement of, or concurrence with, information, conclusions or recommendations made by analysts.

Investor Relations

Glen Kayll
Tel.: 418 651-0003